HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023

Rhea-AI Summary

Harmony Biosciences (NASDAQ: HRMY) will announce its fourth quarter and full year 2022 financial results on February 21, 2023, before U.S. market opening. A conference call will follow at 8:30 a.m. ET for discussing the results. Investors can participate by calling (800) 225-9448 domestically or +1 (203) 518-9708 internationally, with recommended early dial-in. Harmony specializes in therapies for rare neurological diseases and was established in 2017. The company believes in innovative science translating to therapeutic possibilities for patients. Investors can access the live webcast on their investor page.

Positive

• Anticipation for fourth quarter and full year 2022 financial results could drive investor interest.
• Upcoming conference call allows for direct engagement with investors.

Negative

• None.

PLYMOUTH MEETING, Pa., Feb. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on February 21, 2023, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial (800) 225-9448 (domestic) or +1 (203) 518-9708 (international), and reference passcode HRMYQ422. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences 
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com

Harmony Biosciences Media Contact: 
Cate McCanless
202-641-6086 
cmccanless@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-21-2023-301738717.html

SOURCE Harmony Biosciences

FAQ

What date will Harmony Biosciences report its financial results for Q4 and full year 2022?

Harmony Biosciences will report its financial results on February 21, 2023.

What time is the Harmony Biosciences conference call scheduled?

The conference call is scheduled for 8:30 a.m. ET on February 21, 2023.

How can I participate in the Harmony Biosciences conference call?

To participate, call (800) 225-9448 domestically or +1 (203) 518-9708 internationally.

Where can I find the webcast of Harmony Biosciences' call?

The webcast will be available on the investor page of the Harmony Biosciences website.